To include your compound in the COVID-19 Resource Center, submit it here.

Dox-SL data

LTIZ reported on 133 patients from an ongoing European and Australian Phase II open-label study of 247 patients

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE